Atara Biotherapeutics Announces Positive Results from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 63rd American Society of Hematology (ASH) Annual Meeting Dec 13, 2021 7:15pm EST
Atara Biotherapeutics Announces Preliminary Results for ATA2271, a Next-Generation Autologous Mesothelin-targeted CAR T-cell Therapy for Solid Tumors, at ESMO Immuno-Oncology Congress 2021 Dec 09, 2021 8:00am EST
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Dec 03, 2021 4:01pm EST
European Medicines Agency (EMA) Validates Atara Biotherapeutics' Marketing Authorization Application for Tabelecleucel for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease Nov 30, 2021 8:30am EST
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nov 05, 2021 4:01pm EDT
Atara Biotherapeutics to Present Eight Abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting, Including First Presentation of Tab-cel® Pivotal Phase 3 (ALLELE) Data Nov 04, 2021 9:30am EDT
Atara Biotherapeutics Announces Third Quarter 2021 Financial Results and Operational Progress Nov 04, 2021 7:30am EDT
Atara Biotherapeutics to Announce Third Quarter 2021 Financial Results on Thursday, November 4, 2021 Oct 28, 2021 4:01pm EDT
Atara Biotherapeutics Presents New Magnetization Transfer Ratio Imaging Data and Two-Year Clinical Data from the Open Label Extension of ATA188 for Progressive Multiple Sclerosis at ECTRIMS 2021 Oct 13, 2021 7:30am EDT
